{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T17:10:25Z","timestamp":1740676225444,"version":"3.38.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1949,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1124\/jpet.119.257717","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T22:15:16Z","timestamp":1561760116000},"page":"514-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells via Cell Cycle Perturbation"],"prefix":"10.1016","volume":"370","author":[{"given":"Seung-Youn","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ky-Youb","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-In","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Hee","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-7634","authenticated-orcid":false,"given":"Jiyeon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5135-0033","authenticated-orcid":false,"given":"Jong Kuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Duck","family":"Um","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-3708","authenticated-orcid":false,"given":"Sang-Gu","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Un","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-7511","authenticated-orcid":false,"given":"Jie-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.257717_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.119.257717_bib2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrc.2016.18","article-title":"Radiation oncology in the era of precision medicine","volume":"16","author":"Baumann","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.119.257717_bib3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/annonc\/mdp377","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours","volume":"21","author":"Boss","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1124\/jpet.119.257717_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-7-1","article-title":"Determination of cell survival after irradiation via clonogenic assay versus multiple MTT assay\u2014a comparative study","volume":"7","author":"Buch","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1124\/jpet.119.257717_bib5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/ijms19020555","article-title":"Impact of DNA and RNA methylation on radiobiology and cancer progression","volume":"19","author":"Chi","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.119.257717_bib6","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1038\/onc.2010.154","article-title":"Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure","volume":"29","author":"Dean","year":"2010","journal-title":"Oncogene"},{"key":"10.1124\/jpet.119.257717_bib7","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/sj.bjc.6601427","article-title":"Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage\/repair in human colon cancer cells","volume":"89","author":"Dunne","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.119.257717_bib8","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/sj.onc.1206677","article-title":"P53 and radiation responses","volume":"22","author":"Fei","year":"2003","journal-title":"Oncogene"},{"key":"10.1124\/jpet.119.257717_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tips.2011.02.014","article-title":"Anticancer therapy with checkpoint inhibitors: what, where and when?","volume":"32","author":"Garrett","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.119.257717_bib10","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nrd3908","article-title":"Cyclin-dependent kinase inhibitors move into phase III","volume":"11","author":"Guha","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.119.257717_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/jpet.119.257717_bib12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2011.240","article-title":"Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers","volume":"105","author":"Harrington","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.119.257717_bib13","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4155\/fmc-2017-0246","article-title":"Recent advances in CDK inhibitors for cancer therapy","volume":"10","author":"Heptinstall","year":"2018","journal-title":"Future Med Chem"},{"key":"10.1124\/jpet.119.257717_bib14","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1038\/sj.onc.1206682","article-title":"DNA damage checkpoint control in cells exposed to ionizing radiation","volume":"22","author":"Iliakis","year":"2003","journal-title":"Oncogene"},{"key":"10.1124\/jpet.119.257717_bib15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1517\/14728222.2010.525221","article-title":"Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors","volume":"14","author":"Johnson","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"10.1124\/jpet.119.257717_bib16","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3892\/ijo.2017.4141","article-title":"Novel focal adhesion kinase 1 inhibitor sensitizes lung cancer cells to radiation in a p53-independent manner","volume":"51","author":"Jung","year":"2017","journal-title":"Int J Oncol"},{"key":"10.1124\/jpet.119.257717_bib17","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.3892\/or.2015.4249","article-title":"IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling","volume":"34","author":"Jung","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1124\/jpet.119.257717_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3892\/ijo.2014.2720","article-title":"A novel pyrido-thieno-pyrimidine derivative activates p53 through induction of phosphorylation and acetylation in colorectal cancer cells","volume":"46","author":"Kang","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1124\/jpet.119.257717_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1535-7163.513.3.4","article-title":"G2 checkpoint abrogators as anticancer drugs","volume":"3","author":"Kawabe","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.119.257717_bib20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4161\/cc.4.3.1551","article-title":"Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes","volume":"4","author":"Kozar","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.119.257717_bib21","doi-asserted-by":"crossref","first-page":"7224","DOI":"10.1158\/1078-0432.CCR-10-2639","article-title":"Cancer stem cells: targets and potential biomarkers for radiotherapy","volume":"17","author":"Krause","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.119.257717_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"key":"10.1124\/jpet.119.257717_bib23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.freeradbiomed.2012.05.038","article-title":"An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses","volume":"53","author":"Lee","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/jpet.119.257717_bib24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.119.257717_bib25","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.biocel.2012.04.022","article-title":"Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis","volume":"44","author":"Lim","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1124\/jpet.119.257717_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","article-title":"To cycle or not to cycle: a critical decision in cancer","volume":"1","author":"Malumbres","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.119.257717_bib27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s10637-015-0244-4","article-title":"A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer","volume":"33","author":"Mitri","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1124\/jpet.119.257717_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O\u2019Leary","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/jpet.119.257717_bibib46","doi-asserted-by":"crossref","first-page":"R538","DOI":"10.1016\/j.cub.2015.05.010","article-title":"Aneuploidy","volume":"25","author":"Orr","year":"2015","journal-title":"Curr Biol"},{"key":"10.1124\/jpet.119.257717_bibib47","doi-asserted-by":"crossref","first-page":"e1028","DOI":"10.1038\/cddis.2013.535","article-title":"GLI2 induces genomic instability in human keratinocytes by inhibiting apoptosis","volume":"5","author":"Pantazi","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1124\/jpet.119.257717_bib29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2217\/fon.10.104","article-title":"Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation","volume":"6","author":"Pauwels","year":"2010","journal-title":"Future Oncol"},{"key":"10.1124\/jpet.119.257717_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0360-3016(01)01686-8","article-title":"Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation","volume":"51","author":"Petersen","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1124\/jpet.119.257717_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccr.2013.08.027","article-title":"The role of Cdk5 in neuroendocrine thyroid cancer","volume":"24","author":"Pozo","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.119.257717_bib32","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/15384101.2018.1491236","article-title":"CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner","volume":"17","author":"Prevo","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.119.257717_bib33","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.4161\/cc.7.23.7122","article-title":"Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases","volume":"7","author":"Romano","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.119.257717_bib34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nature06046","article-title":"Cdk1 is sufficient to drive the mammalian cell cycle","volume":"448","author":"Santamar\u00eda","year":"2007","journal-title":"Nature"},{"key":"10.1124\/jpet.119.257717_bib35","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1038\/onc.2009.170","article-title":"Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms","volume":"28","author":"Satyanarayana","year":"2009","journal-title":"Oncogene"},{"key":"10.1124\/jpet.119.257717_bib36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin D3:CDK4\/6 complex in T cell leukemia","volume":"22","author":"Sawai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.119.257717_bib37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug-radiotherapy combinations","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/jpet.119.257717_bib38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1124\/jpet.119.257717_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-018-0010-0","article-title":"Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models","volume":"3","author":"Syn","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"10.1124\/jpet.119.257717_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0006-3495(63)86801-0","article-title":"Variations in several responses of HeLa cells to x-irradiation during the division cycle","volume":"3","author":"Terasima","year":"1963","journal-title":"Biophys J"},{"key":"10.1124\/jpet.119.257717_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","article-title":"Inhibitors of cyclin-dependent kinases as cancer therapeutics","volume":"173","author":"Whittaker","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.119.257717_bib42","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.7150\/thno.25487","article-title":"Blocking CDK1\/PDK1\/\u03b2-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma","volume":"8","author":"Wu","year":"2018","journal-title":"Theranostics"},{"key":"10.1124\/jpet.119.257717_bib43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3892\/ijo.2013.2240","article-title":"The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition","volume":"44","author":"Xia","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1124\/jpet.119.257717_bib44","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.ijrobp.2011.02.015","article-title":"Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts","volume":"80","author":"Yaromina","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1124\/jpet.119.257717_bib45","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1073\/pnas.98.4.1682","article-title":"A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene","volume":"98","author":"Ye","year":"2001","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.257717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:53:40Z","timestamp":1740675220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524260699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0022356524260699"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.257717","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells via Cell Cycle Perturbation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.257717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The Author(s)","name":"copyright","label":"Copyright"}]}}